Abstract
The complexity of the tumor microenvironment, associated with genetic heterogeneity and the invasive nature of glioblastoma (GB), make it one of the most resistant neoplasms to antineoplastic therapy. Currently, surgery, with extensive tumor resection, combined with radiotherapy and chemotherapy, is the standard of majority intervention in the treatment of GB. However, such therapeutic st…